Complications of Immunoglobulin Therapy and Implications for Treatment of Inflammatory Neuropathy: A Review

Ahmed Abbas, Yusuf A. Rajabally

Research output: Contribution to journalReview article

Abstract

BACKGROUND: Intravenous Immunoglobulin (IVIg) forms a cornerstone of effective treatment for acute and chronic inflammatory neuropathies, with a class I evidence base in Guillain-Barré Syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and multifocal motor neuropathy (MMN). It is generally considered to be a safe therapy however there are several recognised complications which are reviewed in this article. DISCUSSION AND CONCLUSION: Most adverse events are immediate and mild such as headache, fever and nausea although more serious immediate reactions such as anaphylaxis may rarely occur. Delayed complications are rare but may be serious, including thromboembolic events and acute kidney injury, and these and associated risk factors are also discussed. We emphasise the importance of safe IVIg administration and highlight practical measures to minimise complications of this therapy.

LanguageEnglish
Pages3-13
Number of pages11
JournalCurrent drug safety
Volume14
Issue number1
DOIs
Publication statusPublished - 31 Jan 2019

Fingerprint

Passive Immunization
Intravenous Immunoglobulins
Immunoglobulins
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Guillain-Barre Syndrome
Anaphylaxis
Acute Kidney Injury
Intravenous Administration
Nausea
Headache
Fever
Therapeutics

Keywords

  • Adverse event
  • CIDP
  • GBS
  • immunoglobulin
  • inflammatory neuropathy
  • IVIg
  • MMN
  • safety.

Cite this

@article{6ff98f9364a74f4cb6624cf251ceed2e,
title = "Complications of Immunoglobulin Therapy and Implications for Treatment of Inflammatory Neuropathy: A Review",
abstract = "BACKGROUND: Intravenous Immunoglobulin (IVIg) forms a cornerstone of effective treatment for acute and chronic inflammatory neuropathies, with a class I evidence base in Guillain-Barr{\'e} Syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and multifocal motor neuropathy (MMN). It is generally considered to be a safe therapy however there are several recognised complications which are reviewed in this article. DISCUSSION AND CONCLUSION: Most adverse events are immediate and mild such as headache, fever and nausea although more serious immediate reactions such as anaphylaxis may rarely occur. Delayed complications are rare but may be serious, including thromboembolic events and acute kidney injury, and these and associated risk factors are also discussed. We emphasise the importance of safe IVIg administration and highlight practical measures to minimise complications of this therapy.",
keywords = "Adverse event, CIDP, GBS, immunoglobulin, inflammatory neuropathy, IVIg, MMN, safety.",
author = "Ahmed Abbas and Rajabally, {Yusuf A.}",
year = "2019",
month = "1",
day = "31",
doi = "10.2174/1574886313666181017121139",
language = "English",
volume = "14",
pages = "3--13",
number = "1",

}

Complications of Immunoglobulin Therapy and Implications for Treatment of Inflammatory Neuropathy : A Review. / Abbas, Ahmed; Rajabally, Yusuf A.

Vol. 14, No. 1, 31.01.2019, p. 3-13.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Complications of Immunoglobulin Therapy and Implications for Treatment of Inflammatory Neuropathy

T2 - A Review

AU - Abbas, Ahmed

AU - Rajabally, Yusuf A.

PY - 2019/1/31

Y1 - 2019/1/31

N2 - BACKGROUND: Intravenous Immunoglobulin (IVIg) forms a cornerstone of effective treatment for acute and chronic inflammatory neuropathies, with a class I evidence base in Guillain-Barré Syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and multifocal motor neuropathy (MMN). It is generally considered to be a safe therapy however there are several recognised complications which are reviewed in this article. DISCUSSION AND CONCLUSION: Most adverse events are immediate and mild such as headache, fever and nausea although more serious immediate reactions such as anaphylaxis may rarely occur. Delayed complications are rare but may be serious, including thromboembolic events and acute kidney injury, and these and associated risk factors are also discussed. We emphasise the importance of safe IVIg administration and highlight practical measures to minimise complications of this therapy.

AB - BACKGROUND: Intravenous Immunoglobulin (IVIg) forms a cornerstone of effective treatment for acute and chronic inflammatory neuropathies, with a class I evidence base in Guillain-Barré Syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and multifocal motor neuropathy (MMN). It is generally considered to be a safe therapy however there are several recognised complications which are reviewed in this article. DISCUSSION AND CONCLUSION: Most adverse events are immediate and mild such as headache, fever and nausea although more serious immediate reactions such as anaphylaxis may rarely occur. Delayed complications are rare but may be serious, including thromboembolic events and acute kidney injury, and these and associated risk factors are also discussed. We emphasise the importance of safe IVIg administration and highlight practical measures to minimise complications of this therapy.

KW - Adverse event

KW - CIDP

KW - GBS

KW - immunoglobulin

KW - inflammatory neuropathy

KW - IVIg

KW - MMN

KW - safety.

UR - http://www.scopus.com/inward/record.url?scp=85060825096&partnerID=8YFLogxK

UR - http://www.eurekaselect.com/166355/article

U2 - 10.2174/1574886313666181017121139

DO - 10.2174/1574886313666181017121139

M3 - Review article

VL - 14

SP - 3

EP - 13

IS - 1

ER -